Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EPI-2010
- Development stage
- Unknown
- Lead developer
- Epigenesis
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Inhalation
01
Overview
EPI-2010 is a 21-mer phosphorothioate respirable antisense oligonucleotide (RASON) developed for the treatment of asthma. It specifically targets the mRNA of the adenosine A1 receptor, leading to its degradation and preventing synthesis of new receptor protein. By reducing adenosine A1 receptor expression in the lungs, EPI-2010 attenuates bronchoconstriction, inflammation, and surfactant depletion associated with asthma. The drug is administered via inhalation and has demonstrated potent effects in preclinical models as well as initial clinical trials. Its duration of effect can last up to nearly a week despite a relatively short half-life in lung tissue[2][3][1].
02
Targets
ADORA1 (Adenosine receptor A1 subtype)
Beyond the preview
Go deeper on EPI-2010.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EPI-2010.